Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
2.
J Drugs Dermatol ; 21(8): 819-824, 2022 Aug 01.
Article in English | MEDLINE | ID: mdl-35946977

ABSTRACT

BACKGROUND: Patients treated with biological therapy for hidradenitis suppurativa (HS) are at an increased risk of infectious complications. However, it is unclear whether these patients are at an increased risk of acquiring infections. The most common infection reported in patients taking biologic therapies are respiratory tract infections. The purpose of this study is to review the risk and incidence rate of upper respiratory tract infections (URTI), nasopharyngitis, and influenza in patients treated with biologics for HS. METHODS: A comprehensive literature search was completed using databases (MEDLINE and EMBASE) and clinical trial registries (clinicaltrials.gov) to identify trials that reported the risk and incidence rate of URTIs, nasopharyngitis, and influenza in patients using biological therapy for moderate to severe HS. Each study was assessed for bias using the GRADE system. FINDINGS: There were nine studies included in this review including five placebo-controlled studies of patients with moderate to severe HS treated with biological therapy. We found the risk of URTI, nasopharyngitis, and influenza was not significantly different in patients taking biological therapy when compared to placebo (RR 1.23; 95% CI 0.66-2.30and RR 0.93; 95% CI 0.66-1.31, RR 1.03; 95% CI 0.41-2.56, respectively). CONCLUSIONS: This systematic review and meta-analysis did not find significantly different risks of URTI, nasopharyngitis, and influenza in patients taking biological therapy when compared to placebo. However, these data were limited by the sample size and number of studies available. Future high-quality, high-power, and long-term studies are needed to support the data available on this topic. J Drugs Dermatol. 2022;21(8): 819-824. doi:10.36849/JDD.6433.


Subject(s)
Biological Products , Hidradenitis Suppurativa , Nasopharyngitis , Respiratory Tract Infections , Biological Products/adverse effects , Hidradenitis Suppurativa/drug therapy , Hidradenitis Suppurativa/epidemiology , Humans , Incidence , Respiratory Tract Infections/epidemiology
3.
J Clin Endocrinol Metab ; 104(7): 2648-2656, 2019 07 01.
Article in English | MEDLINE | ID: mdl-30753542

ABSTRACT

BACKGROUND: Evidence suggests that metabolic adaptation occurs after bariatric surgery such that resting energy expenditure (REE) declines more than accounted for by body weight or body composition changes in adults. Little is known about REE and metabolic adaptation among adolescents after bariatric surgery. OBJECTIVE: To examine changes in REE and metabolic adaptation among adolescents at 12 months (12M) after bariatric surgery. SETTING: Pediatric hospital, Canada. METHODS: Adolescents undergoing Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) were followed. Bioelectrical impedance analysis and indirect calorimetry were completed to measure body composition and REE, respectively. Predicted REE was calculated using the Mifflin equation before and after bariatric surgery and a predictive equation using preoperative data. RESULTS: Among 20 patients (15 girls), the mean age and body mass index at surgery were 17.2 ± 0.8 years and 48.7 ± 7.4 kg/m2, respectively. REE had decreased by 548.3 kcal/d at 12M postoperatively (P < 0.001). Metabolic adaptation, determined by two procedures, was negative and significantly different from baseline (P < 0.05). When stratified by surgery type, REE change at 12M was not significantly different (RYGB, -494.0 ± 260.9 kcal/d, n = 11; SG, -614.6 ± 344.4 kcal/d, n = 9; P = 0.384). Among 13 patients with REE data at 6 and 12M, no statistically significant difference was found (P = 0.368). CONCLUSIONS: Predicted and measured REE was 19% and 25% lower at 12M, respectively, irrespective of bariatric surgery type. Metabolic adaptation might predispose adolescents to weight regain after bariatric surgery and warrants careful nutritional management and counseling.


Subject(s)
Adaptation, Physiological , Bariatric Surgery/methods , Energy Metabolism/physiology , Obesity, Morbid/surgery , Pediatric Obesity/surgery , Weight Gain/physiology , Adolescent , Body Composition/physiology , Female , Follow-Up Studies , Humans , Male , Obesity, Morbid/metabolism , Pediatric Obesity/metabolism , Postoperative Period , Rest/physiology , Treatment Outcome , Weight Loss/physiology , Young Adult
4.
Oncotarget ; 9(53): 30034-30052, 2018 Jul 10.
Article in English | MEDLINE | ID: mdl-30046386

ABSTRACT

Breast cancer is a leading cause of cancer mortality. In particular, triple negative breast cancer (TNBC) comprise a heterogeneous group of basal-like tumors lacking estrogen receptor (ERα), progesterone receptor (PR) and HER2 (ErbB2). TNBC represents 15-20% of all breast cancers and occurs frequently in women under 50 years of age. Unfortunately, these patients lack targeted therapy, are typically high grade and metastatic at time of diagnosis. The mechanisms regulating metastasis remain poorly understood. We have previously shown that the kisspeptin receptor, KISS1R stimulates invasiveness of TNBC cells. In this report, we demonstrate that KISS1R signals via the secreted extracellular matrix protein, fibulin-3, to regulate TNBC invasion. We found that the fibulin-3 gene is amplified in TNBC primary tumors and that plasma fibulin-3 levels are elevated in TNBC patients compared to healthy subjects. In this study, we show that KISS1R activation increases fibulin-3 expression and secretion. We show that fibulin-3 regulates TNBC metastasis in a mouse experimental metastasis xenograft model and signals downstream of KISS1R to stimulate TNBC invasion, by activating matrix metalloproteinase 9 (MMP-9) and the MAPK pathway. These results identify fibulin-3 as a new downstream mediator of KISS1R signaling and as a potential biomarker for TNBC progression and metastasis, thus revealing KISS1R and fibulin-3 as novel drug targets in TNBC.

5.
J Toxicol Environ Health B Crit Rev ; 11(3-4): 345-50, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18368560

ABSTRACT

Public perception of the negative effects of endocrine-disrupting chemicals appears to be higher compared to other chemical pollutants, due to (1) chronic, low-probability effects, and (2) uncertainties about which biological effects may be relevant for human health. Individuals, both expert and lay public, require credible, trustworthy, and understandable information about the scientific evidence of endocrine-disrupting chemicals in order to make informed risk decisions. The creation of a dedicated web site, http://www.emcom.ca, as a tool for knowledge translation and transfer provides the general public with access to scientific experts and bridges the gap between experts and nonexperts through a two-way, interactive communications approach. By obtaining accurate and credible information, individuals can make better-informed decisions concerning endocrine-disrupting chemicals.


Subject(s)
Endocrine Disruptors , Environmental Exposure/adverse effects , Information Services/standards , Internet , Endocrine Disruptors/adverse effects , Health Education , Health Knowledge, Attitudes, Practice , Humans , Public Opinion , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...